Concept information
Preferred term
Procarbazine
Type
-
mesh:Descriptor
Definition
- An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
Broader concept
Entry terms
- 13309-74-5 (HCl)
- 18969-59-0 (mono-HBr)
- 35S93Y190K
- 366-70-1 (mono-HCl)
- 671-16-9 (Procarbazine)
- Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-
- XH0NPH5ZX8
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analogs & derivatives (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- economics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
13309-74-5 (HCl)
-
18969-59-0 (mono-HBr)
-
35S93Y190K
-
366-70-1 (mono-HCl)
-
671-16-9 (Procarbazine)
-
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-
-
XH0NPH5ZX8
URI
http://data.loterre.fr/ark:/67375/JVR-DNG7CKMV-N
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}